Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy

Clinical Therapeutics

Volumn 21, Issue 1, 1999, Pages 218-235

  Bottorff, Michael B ^a   Yenkowsky, Joseph P ^b   Cave, Douglas G ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Allina Hospitals & Clinics   (United States)

^c Practice Patterns Science Inc   (United States)

Author keywords

Drug interactions; HMG CoA reductase inhibitors; Lovastatin; Pravastatin; Simvastatin

Indexed keywords

ASTEMIZOLE; ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NEFAZODONE; PRAVASTATIN; SIMVASTATIN; TERFENADINE;

ARTICLE; CARDIOVASCULAR DISEASE; COST OF ILLNESS; DATA BASE; DIAGNOSIS RELATED GROUP; DISEASE SEVERITY; DRUG COST; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; OUTPATIENT; SCORING SYSTEM;

EID: 0032971082     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88280-6     Document Type: Article

References (47)

1. 1. Leape LL, Brennan TA, Laird NM, et al. The nature of adverse events in hospitalized patients: Results of the Harvard Medical Practice Study II. NEJM. 1991; 324:377-384.
2. 2. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: Results of the Harvard Medical Practice Study 1. NEJM. 1991;324:370-376.
3. 3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998;279: 1200-1205.
4. 4. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med. 1995;155: 1949-1956.
5. 5. Moore N, Lecointre D, Noblet C, et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol., 1998;45: 301-308.
6. 6. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use: A study of community-dwelling persons 65 years of age and older. Ann Intern Med. 1992;117:634-640.
7. 7. Mullins ME, Horowitz BZ, Linden DH, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA. 1998:280:157-158.
8. 8. Carpenter CE, Bender AD, Nash DB, et al. Must we choose between quality and cost containment? Qual Health Care. 1996;5:223-229.
9. 9. Kurata JH, Overhage M, Gabrieli E, et al. International data standards for hospital-based drug surveillance. MD Comput. 1995;12:50-57.
10. 10. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-306.
11. 11. Azaz-Livshits T, Levy M, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: Pilot study. Br J Clin Pharmacol. 1998;45:309-314.
12. 12. Classen DC, Pestotnik SL, Evans RS, et al. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266:2847-2851.
13. 13. Kahn KL. Above all "do no harm": How shall we avoid errors in medicine? JAMA. 1995;274:75-76. Editorial.
14. 14. Cave DG, Geehr EC. Analyzing patterns-of-treatmem data to provide feedback to physicians. Med Interface. 1994;7:117-128.
15. 15. Cave DG. Profiling physician practice patterns using diagnostic episode clusters. Med Care. 1995;33:463-486.
16. 16. Wray NP, Hollingsworth JC, Petersen NJ, et al. Case-mix adjustment using administrative databases: A paradigm to guide future research. Med Care Res Rev. 1997;54:326-356.
17. 17. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
18. 18. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther. 1997;62:311-321.
19. 19. Kliem V, Wanner C, Eisenhauer T, et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc. 1996;28: 3126-3128.
20. 20. Food and Drug Administration. Warning labeling changes for new drug Posicor. FDA Talk Paper. T97-65:1-4. December 19, 1997.
21. 21. Ernst ME, Kelly MW. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy. 1998;18:463-485.
22. 22. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 1998;351:1929-1930. Letter.
23. 23. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-341.
24. 24. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63: 397-402.
25. 25. Azie NE, Brater DC, Becker PA, et al. Interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998; 64:369-377.
26. 26. Kantola T, Kivisto K, Neuvonen P. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64:58-65.
27. 27. Dartnell JGA, Anderson RP, Chohan V, et al. Hospitalization for adverse events related to drug therapy: Incidence, avoid-ability and costs. Med J Aust. 1996; 164:659-662.
28. 28. Bates DW, Spell N, Cullen DJ, et al, for the Adverse Drug Events Prevention Study Group. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-311.
29. 29. Borchelt M. Potential side-effects and interactions in multiple medication in elderly patients: Methodology and results of the Berlin Study of Aging. Z Gerontol Geriatr. 1995;28:420-428.
30. 30. Bergendal L, Friberg A, Schaffrath A. Potential drug-drug interactions in 5,125 mostly elderly out-patients in Gothenburg, Sweden. Pharm World Sci. 1995;17: 152-157.
31. 31. Tamblyn R. Medication use in seniors: Challenges and solutions. Therapie. 1996; 51:269-282.
32. 32. Schneeweiss R, Rosenblatt RA, Cherkin DC, et al. Diagnostic clusters: A new tool for analyzing the content of ambulatory medical care. Med Care 1983;21:105-122.
33. 33. International Classification of Diseases: 9th Revision. ICD-9. 4th ed. Washington, DC: US Department of Health and Human Services; 1991.
34. 34. Physician's Current Procedural Terminology: CPT. 4th ed. Chicago, III: American Medical Association; 1984.
35. 35. Baker T, Ertle A, Cave DG. Challenges to identifying actual diabetes case-mix complexity and total treatment charges. Med Interface. 1997;10:91-96.
36. 36. Gonella J. Disease Staging Clinical Criteria. 3rd ed. New York: Systemetrics; 1986.
37. 37. Winer BJ, Michels KM, Brown DR, eds. Statistical Principles in Experimental Design. 3rd ed. New York; McGraw-Hill; 1991.
38. 38. Oster G, Borok GM, Menzin J, et al. Cholesterol-Reduction Intervention Study (CRIS). A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med. 1996;156:731-739.
39. 39. Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease. Arch Intern Med. 1998;157:375-381.
40. 40. Langley PC. Cost-effectiveness profiles with an expanding treatment population. Clin Ther. 1995;17:1207-1212.
41. 41. Herbert J. Indirect drug-related costs. Lancet. 1995;345:588-589. Letter.
42. 42. Evans RS, Classen DC, Stevens LE, et al. Using a hospital information system to assess the effects of adverse drug events. In: Proceedings of the 17th Annual Symposium on Computer Applications in Medical Care. 1993;161-165.
43. 43. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;33:1301-1307.
44. 44. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
45. 45. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279:1615-1622.
46. 46. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 1996;335:1001-1009.
47. 47. McGettigan P, Golden J, Conroy tervention. Br J Clin Pharmacol. 1997; 44:98-100.